FIGURE 1 from Single-Cell CD4 and CD8 T-Cell Secretome Profiling Reveals Temporal and Niche Differences in Acute Myeloid Leukemia Following Immune Checkpoint Blockade Therapy

Integrative analysis approach and clinical characteristic profile of patient cohort. A, Clinical characteristics of RelRef AML cohort for 21 patients involved in the phase II clinical trial. Among the 21 patients enrolled, 20 had baseline PB samples, 16 had baseline BM samples, 10 had posttreatment PB samples, and 6 had posttreatment BM samples. Four patients had prior allogeneic stem cell transplantation (all-SCT) therapy; 11 patients had prior HMA therapy; 11 patients had Secondary AML; 10 patients had CR to Aza/Nivo immunotherapy in the phase II clinical trial; Karyotype and molecular diagnostics at baseline for all 21 patients are included. B, Venn diagram visualizing the patient cohort.